SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
Molecular Oncology · 2024
DOI: 10.1002/1878-0261.13564 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Patricia L Theard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Acrylamides, Aniline Compounds. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, DOD Peer Reviewed Cancer Research Program, Office of Extramural Research, National Institutes of Health.
Abstract (Originalsprache)
Son of sevenless 1 and 2 (SOS1 and SOS2) are RAS guanine nucleotide exchange factors (RasGEFs) that mediate physiologic and pathologic receptor tyrosine kinase (RTK)‐dependent RAS activation. Here, we show that SOS2 modulates the threshold of epidermal growth factor receptor (EGFR) signaling to regulate the efficacy of and resistance to the EGFR tyrosine kinase inhibitor (EGFR‐TKI) osimertinib in lung adenocarcinoma (LUAD). SOS2 deletion ( SOS2 KO ) sensitized EGFR ‐mutated cells to perturbations in EGFR signaling caused by reduced serum and/or osimertinib treatment to inhibit phosphatidylinositol 3‐kinase (PI3K)/AKT pathway activation, oncogenic transformation, and survival. Bypassing RTK reactivation of PI3K/AKT signaling represents a common resistance mechanism to EGFR‐TKIs; SOS2 KO reduced PI3K/AKT reactivation to limit osimertinib resistance. In a forced HGF/MET‐driven bypass model, SOS2 KO inhibited hepatocyte growth factor (HGF)‐stimulated PI3K signaling to block HGF‐driven osimertinib resistance. Using a long‐term in situ resistance assay, most osimertinib‐resistant cultures exhibited a hybrid epithelial/mesenchymal phenotype associated with reactivated RTK/AKT signaling. In contrast, RTK/AKT‐dependent osimertinib resistance was markedly reduced by SOS2 deletion; the few SOS2 KO cultures that became osimertinib resistant primarily underwent non‐RTK‐dependent epithelial–mesenchymal transition (EMT). Since bypassing RTK reactivation and/or tertiary EGFR mutations represent most osimertinib‐resistant cancers, these data suggest that targeting proximal RTK signaling, here exemplified by SOS2 deletion, has the potential to delay the development osimertinib resistance and enhance overall clinical responses for patients with EGFR ‐mutated LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
ORCID-Profile: Robert L Kortum
Förderung
- NCI NIH HHS
- DOD Peer Reviewed Cancer Research Program
- Office of Extramural Research, National Institutes of Health
Zitieren
APA
Theard, P. L., Linke, A. J., Sealover, N. E., Daley, B. R., Yang, J., Cox, K., & Kortum, R. L. (2024). SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.13564
Vancouver
Theard PL, Linke AJ, Sealover NE, Daley BR, Yang J, Cox K, et al. SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma. Molecular Oncology. 2024. doi:10.1002/1878-0261.13564
BibTeX
@article{Theard2024,
author = {Theard, Patricia L and Linke, Amanda J and Sealover, Nancy E and Daley, Brianna R and Yang, Johnny and Cox, Katherine and Kortum, Robert L},
title = {SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma},
journal = {Molecular Oncology},
year = {2024},
doi = {10.1002/1878-0261.13564}
}
EUVIMED